Anticoagulation in coronary intervention
作者： Uwe Zeymer , Sunil V. Rao , Gilles Montalescot
关键词: Bivalirudin 、 Medicine 、 Conventional PCI 、 Internal medicine 、 Coronary artery disease 、 Myocardial infarction 、 Heparin 、 Cardiology 、 Percutaneous coronary intervention 、 Direct thrombin inhibitor 、 Randomized controlled trial
摘要: Percutaneous coronary intervention (PCI) induces thrombin generation and is associated with the risk of acute, subacute, or long-term ischaemic events. Therefore, intravenous anticoagulation recommended to minimize thrombotic complications. The intensity duration needed are dependent on clinical presentation (elective PCI for stable artery disease, non-ST elevation acute syndromes, primary ST-segment myocardial infarction) procedural features. As both periprocedural bleeding complications mortality, optimal level best agents a matter debate. Despite number limitations lack large randomized trials, unfractionated heparin (UFH) still been used in majority interventions. Intravenous enoxaparin, low-molecular-weight heparin, leads more predictable has compared UFH patients elective favourable results. direct inhibitor bivalirudin studied numerous trials consistently shown reduce when without glycoprotein IIb/IIIa inhibitors. This review will summarize current status results most recent give recommendations different scenarios.
oup.com
oxfordjournals.org
sci-hub.se 参考文章(66)
Peter Clemmensen, Sebastian Wiberg, Arnoud van't Hof, Efthymios N. Deliargyris, Pierre Coste, Jurrien ten Berg, Claudio Cavallini, Martial Hamon, Dariusz Dudek, Uwe Zeymer, Xavier Tabone, Steen D. Kristensen, Debra Bernstein, Prodromos Anthopoulos, Jayne Prats, Philippe Gabriel Steg, Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention : Insights From the EUROMAX Trial (European Ambulance Acute Coronary Syndrome Angiography) Jacc-cardiovascular Interventions. ,vol. 8, pp. 214- 220 ,(2015) , 10.1016/J.JCIN.2014.11.002
Salim Yusuf, Shamir R Mehta, Susan Chrolavicius, Janine Pogue, Christopher B Granger, Andrzej Budaj, Ron JG Peters, Jean-Pierre Bassand, Lars Wallentin, Campbell Joyner, Keith AA Fox, None, Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial JAMA. ,vol. 295, pp. 1519- 1530 ,(2006) , 10.1001/JAMA.295.13.JOC60038
Sunil V. Rao, Lisa A. McCoy, John A. Spertus, Ronald J. Krone, Mandeep Singh, Susan Fitzgerald, Eric D. Peterson, An Updated Bleeding Model to Predict the Risk of Post-Procedure Bleeding Among Patients Undergoing Percutaneous Coronary Intervention: A Report Using an Expanded Bleeding Definition From the National Cardiovascular Data Registry CathPCI Registry Jacc-cardiovascular Interventions. ,vol. 6, pp. 897- 904 ,(2013) , 10.1016/J.JCIN.2013.04.016
Gregg W. Stone, Tim Clayton, Efthymios N. Deliargyris, Jayne Prats, Roxana Mehran, Stuart J. Pocock, Reduction in Cardiac Mortality With Bivalirudin in Patients With and Without Major Bleeding Journal of the American College of Cardiology. ,vol. 63, pp. 15- 20 ,(2014) , 10.1016/J.JACC.2013.09.027
Marco Valgimigli, Enrico Frigoli, Sergio Leonardi, Martina Rothenbühler, Andrea Gagnor, Paolo Calabrò, Stefano Garducci, Paolo Rubartelli, Carlo Briguori, Giuseppe Andò, Alessandra Repetto, Ugo Limbruno, Roberto Garbo, Paolo Sganzerla, Filippo Russo, Alessandro Lupi, Bernardo Cortese, Arturo Ausiello, Salvatore Ierna, Giovanni Esposito, Patrizia Presbitero, Andrea Santarelli, Gennaro Sardella, Ferdinando Varbella, Simone Tresoldi, Nicoletta De Cesare, Stefano Rigattieri, Antonio Zingarelli, Paolo Tosi, Arnoud van’t Hof, Giacomo Boccuzzi, Elmir Omerovic, Manel Sabaté, Dik Heg, Peter Jüni, Pascal Vranckx, None, Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes The New England Journal of Medicine. ,vol. 373, pp. 997- 1009 ,(2015) , 10.1056/NEJMOA1507854
Gjin Ndrepepa, Peter B. Berger, Julinda Mehilli, Melchior Seyfarth, Franz-Josef Neumann, Albert Schömig, Adnan Kastrati, Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. Journal of the American College of Cardiology. ,vol. 51, pp. 690- 697 ,(2008) , 10.1016/J.JACC.2007.10.040
Eugenio Stabile, Wail Nammas, Luigi Salemme, Giovanni Sorropago, Angelo Cioppa, Tullio Tesorio, Vittorio Ambrosini, Esther Campopiano, Gregory Popusoi, Giuseppe Biondi Zoccai, Paolo Rubino, The CIAO (Coronary Interventions Antiplatelet-based Only) Study Journal of the American College of Cardiology. ,vol. 52, pp. 1293- 1298 ,(2008) , 10.1016/J.JACC.2008.07.026
Roxana Mehran, Stuart Pocock, Eugenia Nikolsky, George D. Dangas, Tim Clayton, Bimmer E. Claessen, Adriano Caixeta, Frederick Feit, Steven V. Manoukian, Harvey White, Michel Bertrand, E. Magnus Ohman, Helen Parise, Alexandra J. Lansky, A. Michael Lincoff, Gregg W. Stone, Impact of Bleeding on Mortality After Percutaneous Coronary Intervention: Results From a Patient-Level Pooled Analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trials Jacc-cardiovascular Interventions. ,vol. 4, pp. 654- 664 ,(2011) , 10.1016/J.JCIN.2011.02.011
Pascal Vranckx, Frank Leebeek, Jan Tijssen, Jacques Koolen, Francis Stammen, Jean-Paul Herman, Robbert de Winter, Arnout van t Hof, Bianca Backx, Wietze Lindeboom, So-Young Kim, Bodo Kirsch, Martin van Eickels, Frank Misselwitz, Freek Verheugt, Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial. Thrombosis and Haemostasis. ,vol. 114, pp. 258- 267 ,(2015) , 10.1160/TH15-01-0061